Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incidence and mortality of multiple myeloma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016
Jiangmei Liu, Weiping Liu, Lan Mi, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 107

Showing 26-50 of 107 citing articles:

Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial
Zhongjun Xia, Yun Leng, Baijun Fang, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA‐specific CAR‐T therapy: A retrospective analysis of LEGEND‐2
Rui Liu, Rui Yang, Xuezhu Xu, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 5, pp. 1780-1789
Open Access | Times Cited: 3
The momentous role of N6‐methyladenosine in lung cancer
Ruiyao Xu, Gaozong Pang, Qing Zhao, et al.
Journal of Cellular Physiology (2020) Vol. 236, Iss. 5, pp. 3244-3256
Closed Access | Times Cited: 26
An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy
Sameer Quazi
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 22, Iss. 6, pp. e392-e404
Open Access | Times Cited: 22
Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma
Grzegorz Charliński, David H. Vesole, Artur Jurczyszyn
Cancers (2021) Vol. 13, Iss. 18, pp. 4666-4666
Open Access | Times Cited: 20
Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience
Wei Sun, Aibin Liang, He Huang, et al.
Haematologica (2023) Vol. 108, Iss. 8, pp. 2011-2028
Open Access | Times Cited: 8
Burden of multiple myeloma in China: an analysis of the Global Burden of Disease, Injuries, and Risk Factors Study 2019
Jiangmei Liu, Weiping Liu, Lan Mi, et al.
Chinese Medical Journal (2023)
Open Access | Times Cited: 8
A circular RNA derived from PLXNB2 as a valuable predictor of the prognosis of patients with acute myeloid leukaemia
Leilei Lin, Yu Wang, Sicheng Bian, et al.
Journal of Translational Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 19
Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study
Huishou Fan
Cancer Biology and Medicine (2023) Vol. 20, Iss. 1, pp. 77-87
Open Access | Times Cited: 7
N6-methyladenosine-induced miR-182-5p promotes multiple myeloma tumorigenesis by regulating CAMK2N1
Jing Bao, Tingting Xu, Wanjie Wang, et al.
Molecular and Cellular Biochemistry (2024) Vol. 479, Iss. 11, pp. 3077-3089
Closed Access | Times Cited: 2
National and subnational mortality trends of multiple myeloma in China, 2013–2020: Empirical evidence from national mortality
Xiaosheng Ding, Xiaoyan Li, Peng Yin, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e32996-e32996
Open Access | Times Cited: 2
Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models
Qianwen Cheng, Li Cai, Yuyang Zhang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 16
Recent advances of microcalorimetry for studying cellular metabolic heat
Ye Wang, Hanliang Zhu, Jianguo Feng, et al.
TrAC Trends in Analytical Chemistry (2021) Vol. 143, pp. 116353-116353
Closed Access | Times Cited: 16
Secular Trends in the Burden of Multiple Myeloma From 1990 to 2019 and Its Projection Until 2044 in China
Yumei Zhao, Dongdong Niu, Enlin Ye, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 11
CD38-targeted and erythrocyte membrane camouflaged nanodrug delivery system for photothermal and chemotherapy in multiple myeloma
F Zhang, Qin Yang, Sishi Tang, et al.
International Journal of Pharmaceutics (2023) Vol. 643, pp. 123241-123241
Open Access | Times Cited: 6
Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study—Asian Subgroup Analysis
Shang‐Yi Huang, Sung‐Soo Yoon, Kazuyuki Shimizu, et al.
Advances in Therapy (2020) Vol. 37, Iss. 7, pp. 3404-3416
Open Access | Times Cited: 17
Synthesis and evaluation of the anticancer activity of [Pt(diimine)(N,N-dibutyl-N′-acylthiourea)]+ complexes
Tebogo Peega, Rachael N. Magwaza, Leonie Harmse, et al.
Dalton Transactions (2021) Vol. 50, Iss. 34, pp. 11742-11762
Closed Access | Times Cited: 14
Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma
Hua Zhang, Jintong Chen, Mingyue Zhang, et al.
Medical Oncology (2022) Vol. 39, Iss. 5
Open Access | Times Cited: 9
The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity
Yue Wang, Jiadai Xu, Tianwei Lan, et al.
Cancer Medicine (2023) Vol. 12, Iss. 24, pp. 21651-21665
Open Access | Times Cited: 5
Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China
Wen Gao, Yurong Zheng, Runhua Zhang, et al.
Cancer Epidemiology (2022) Vol. 78, pp. 102168-102168
Closed Access | Times Cited: 8
Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling
Jin Wang, Yi Hu, Habib Hamidi, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China
Zhe Zhuang, Ying Tian, Lei Shi, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Update on the outcome of M‐protein screening program of multiple myeloma in China: A 7‐year cohort study
Wenjing Wang, Jing Li, Yang Yang, et al.
Cancer Medicine (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Identification of HIST1H2BH as the hub gene associated with multiple myeloma using integrated bioinformatics analysis
Wenxue Zhang, Xian Chen, Zhe Wang, et al.
Hematology (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 1
Construction of the prediction model for multiple myeloma based on machine learning
Jiangying Cai, Zhenhua Liu, Yingying Wang, et al.
International Journal of Laboratory Hematology (2024) Vol. 46, Iss. 5, pp. 918-926
Closed Access | Times Cited: 1

Scroll to top